Swiss Drugmaker Roche Joins Race for Obesity Drugs With $2.7 Billion Deal for Carmot Therapeutics

Swiss pharmaceutical giant Roche agreed to take over obesity drug developer Carmot Therapeutics for $2.7 billion, joining a list global contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk and Eli Lilly.

The U.S. takeover target’s most promising drug candidate, a once-a-week injection called CT-388, belongs to a class known as a dual GLP-1/GIP receptor agonist, the same as Lilly’s Mounjaro, or Zepbound.

After encouraging Phase I trial results, the drug is ready to be tested on humans in the second of three trial stages, Roche added in a statement on Monday.

Read the source article at CNBC